Clinical Edge Journal Scan

Meta-analysis Identifies Unique Risk Factors of Triple-Negative Breast Cancer


 

Key clinical point: The risk factors for overall breast cancer (such as parity, menopausal hormone therapy use, and alcohol consumption) did not increase the risk for triple-negative breast cancer (TNBC), which had a distinct risk factor profile.

Major finding: Parity, menopausal hormone therapy use, alcohol consumption, smoking, and higher body mass index were not significantly associated with TNBC risk (all P > .05); instead, family history (odds ratio [OR] 1.55; P < .001), longer duration of oral contraceptive use (OR 1.29; P < .001), and higher breast density (OR 2.19; P < .001) were significantly associated with an increased risk for TNBC.

Study details: This meta-analysis evaluated the association between TNBC incidence and established BC risk factors using data from 33 studies.

Disclosures: This study was supported by grants from the American Cancer Society and Royal College of Surgeons in Ireland - Medical University of Bahrain (RCSI-MUB Bahrain). The authors declared no conflicts of interest.

Source: Kumar N, Ehsan S, Banerjee S, et al. The unique risk factor profile of triple negative breast cancer: A comprehensive meta-analysis. J Natl Cancer Inst. 2024 (Mar 5). Doi: 10.1093/jnci/djae056 Source

Recommended Reading

Look Beyond BMI: Metabolic Factors’ Link to Cancer Explained
MDedge Hematology and Oncology
MRI Surveillance Reduces Breast Cancer Mortality in Women with BRCA1 Sequence Variation
MDedge Hematology and Oncology
Hyperbaric Oxygenation May Reduce Late Local Toxic Effects After Breast Cancer Irradiation
MDedge Hematology and Oncology
Enobosarm Shows Antitumor Activity in ER+ Advanced BC in Phase 2
MDedge Hematology and Oncology
Doxorubicin May Raise Breast Cancer Risk in Hodgkin Lymphoma Survivors
MDedge Hematology and Oncology
Breast-Conserving Surgery Does Not Increase Locoregional Recurrence in TNBC
MDedge Hematology and Oncology
Obesity and Family History of Cancer Raise Breast Cancer Risk
MDedge Hematology and Oncology
Axillary Lymph Node Dissection Can Be Safely Skipped in Breast Cancer Patients Undergoing Mastectomy
MDedge Hematology and Oncology
Real-World Study Supports Everolimus + Exemestane as HR+/HER2− BC Treatment
MDedge Hematology and Oncology
Pro-Vegetarian Diet May Lower Risk for Breast Cancer
MDedge Hematology and Oncology